Showing 1 - 8 of 8 Eric Bernicker

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

The purpose of this study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy. This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicente ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Meena Medepalli

Phone: 713.441.4203

To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab. ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutation ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Meena Medepalli

Phone: 713.441.4203

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Meena Medepalli

Phone: 713.441.4203

This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in diffe ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Georgia Michou

Phone: 713.441.1952

This is a Phase II trial to determine the efficacy and safety of in situ gene therapy and stereotactic body radiation therapy (SBRT) used as a window of opportunity treatment before nivolumab in patients with metastatic squamous and non-squamous ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Meena Medepalli

Phone: 713.441.4203

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop t ... Read more >

Live Chat Available